Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from AlloVir ( (ALVR) ).
AlloVir, Inc. has announced a merger with Kalaris Therapeutics to form a company focused on retinal diseases, leveraging Kalaris’ TH103 therapy, a novel anti-VEGF treatment. The merger will see Kalaris stockholders own a majority stake, with the combined entity expected to have $100 million in cash, potentially supporting operations into late 2026. The move is set to accelerate the clinical development of TH103, which is currently in Phase 1 trials for neovascular age-related macular degeneration, with results anticipated by Q3 2025.
See more data about ALVR stock on TipRanks’ Stock Analysis page.